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MicroRNAs (miRNAs) are now recognized as essential regulators of gene expression in
plants and animals. They potentially modulate the expression of multiple genes thereby
enabling homeostatic settings in physiological conditions. Their role is also increasingly
considered in many diseases in which deregulated epigenetic mechanisms induce aber-
rant gene expression.Work conducted in our laboratory has recently led to the identification
of miRNAs essential for the control of inflammatory reactions that occur during rheumatoid
arthritis (RA). In this review, we describe two such miRNAs, members of the miR-17∼ 92
cluster, which has been previously implicated in cancer. Based on our data and on predicted
miRNA:mRNA interactions, we will extrapolate a model whereby the miR-17∼92 cluster
appears as a global regulator of the Apoptosis Signal-Regulating Kinase 1 signalosome, a
central actor in the inflammatory pathways activated during RA. We will also discuss the
potential therapeutic outcomes emerging from this model.
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INTRODUCTION
MicroRNAs (miRNAs) are small (∼22 nt long) non-coding RNAs
that appear central to the adjustment of gene expression in a large
number of multicellular as well as a few unicellular organisms
(Krol et al., 2010). Upon binding of their 5′ extremity, also called
the seed sequence (encompassing nucleotides 2–7 or 2–8) with a
complementary site located most of the time in the 3′ untranslated
region (3′UTR) of target mRNAs, miRNAs alter gene expression
by various mechanisms such as translational repression or RNA
degradation (Esteller, 2011; Pasquinelli, 2012). This limited base
pairing interaction between miRNA and mRNA entitles that a vast
number of genes may be targeted by a single miRNA, an assessment
that was experimentally verified (Guo et al., 2010; Mukherji et al.,
2011). Consequently, miRNA-dependent regulation has become
increasingly important for most (if not all) biological mechanisms
[such as development (Stefani and Slack, 2008)] and its alteration
is suspected to occur in multiple pathological conditions (Mendell
and Olson, 2012; O’Connell et al., 2012).
Interestingly, while multiple miRNAs are expressed individu-
ally and scattered across the entire genome, several of them are
clustered and expressed as polycistronic precursors. This enables
co-expression of several miRNAs at similar levels. Furthermore,
it was demonstrated that clustered miRNAs are more efficient
at regulating a complex pathway than separate miRNAs. Indeed,
miRNAs grouped into clusters seem to act cooperatively and in a
coordinated fashion to perform their regulatory functions at dif-
ferent levels of a gene network. The emergence of miRNA clusters
is a recent event during evolution and most of them appear to
be well conserved across vertebrate species. Such a high degree of
conservation and stability indicates that the expression of miRNA
clusters is subjected to strict regulation and that within the clusters
the miRNAs are themselves functionally constrained (Sun et al.,
2013). In this review, we report our recent observations of the
involvement of miRNAs encoded by the cluster miR-17∼ 92 in
the pathogenesis of Rheumatoid Arthritis (RA). Furthermore, we
discuss the potential role of this miRNA cluster in the activa-
tion and regulation of the Mitogen-Activated Protein 3 Kinase
(MAP3K) Apoptosis signal-regulating kinase 1 (ASK1), a central
component of the inflammatory response triggered by Toll-like
Receptors (TLRs) ligands in synovial fibroblasts.
THE miR-17∼ 92 CLUSTER AND CANCER
Among the miRNA clusters analyzed in higher vertebrates, miR-
17∼ 92 has been the focus of intense attention because of its role as
a potential oncogene, hence its other name, OncomiR-1 (He et al.,
2005). This cluster, located on human chromosome 13 (chrom. 14
in mice) encodes a polycistronic miRNA gene which is matured
into six functional miRNAs, miR-17, miR-18a, miR-19a, miR-20,
miR-19b, and miR-92 which are grouped in four families based on
their seed sequence. The oncogenic role of the cluster miR-17∼ 92
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was first evidenced by the observation that the corresponding
locus is frequently amplified in some lymphomas and solid tumors
(Mendell, 2008; Olive et al., 2010). In addition, individual miRNAs
of this cluster interact with several genes and pathways involved in
tumorigenesis. miRNA-dependent targeting of negative regulators
of Phosphatidylinositol-3OH Kinase (PI3K) or B cell lymphoma 2
(BCL-2) family members has been described (Lujambio and Lowe,
2012). E2F transcription factors, which are critical cell cycle reg-
ulators and also control apoptosis, also appear to be regulated
by miRNAs encoded by the miR-17∼ 92 cluster. Interestingly,
these transcriptional regulators directly affect the expression of the
cluster, thus establishing a negative feedback loop. Finally, c-Myc
induction of the cluster contributes to its oncogenic role through
the targeting of antiangiogenic factors such as thrombospondin-1
(Tsp1) or connective tissue growth factor (CTGF) (Mendell, 2008).
Altogether, expression studies performed with human samples as
well as investigations in several mouse models, in which the cluster
miR-17∼ 92 was either overexpressed (Li et al., 2012) or deleted
(Ventura et al., 2008), indicate that this cluster plays important
roles in cancer development.
A detailed analysis of the role of this cluster in neuroblastoma
cells was recently performed to understand its global role and iden-
tify miRNA target genes in a well-defined cancer model (Mestdagh
et al., 2010). Using mass spectrometry to identify changes in pro-
tein contents upon tetracycline-induced miR-17∼ 92 over expres-
sion,perturbation in TGF-β signaling was observed at multiple lev-
els. This study demonstrates that the miR-17∼ 92 cluster weakens
TGF-β signaling through interaction of individual miRNAs with
multiple actors of the pathway, both upstream and downstream
of SMAD2 and SMAD4 transcription factors. This possibility to
control several steps of a signaling cascade underscores the ability
of the miR-17∼ 92 cluster to tightly regulate TGF-β-dependent
transduction cascades. This offers a tremendous opportunity to
modulate the entire TGF-β-dependant transcription program via
inhibition of miR-17∼ 92, for instance using antagomirs.
miRNAs AND RHEUMATOID ARTHRITIS
In addition to their role in cancer, miRNAs have also been involved
in the regulation of many aspects of immune responses, from
the release of inflammatory mediators to antibody production
or helper T cells differentiation (Tsitsiou and Lindsay, 2009;
Tomankova et al., 2011). Therefore, miRNA abnormal expression
was associated with several immune-related disease such as inflam-
matory disorders (O’Connell et al., 2012). Among those, RA is a
frequent (1% of the US population is affected) chronic inflam-
matory autoimmune disease affecting the joints and which can
lead to major distress and substantial morbidity (Duroux-Richard
et al., 2012). The involvement of miRNAs in RA pathogenesis
was first evidenced by the identification, in the serum of RA
patients, of auto-antibodies directed against components of the
P bodies, which are intracellular structures important for RNA
silencing (Jakymiw et al., 2006; Bhanji et al., 2007). More recently,
expression studies uncovered altered miRNA production in the
serum of RA patients compared to controls. Using microarray
analysis, several miRNAs exhibiting a disease-dependent mod-
ified expression pattern (either up or down modulation) were
identified in the mesenchymal compartment (the synoviocyte)
or in immune cells (Wittmann and Jack, 2011). Not surpris-
ingly, miRNAs already described as important modulators of
immune responses, such as miR-155 or miR-146, were identi-
fied in these studies. Importantly, a prominent role for miR-
155 in experimental arthritis was observed using knockout mice,
thereby confirming the major role attributed to this miRNA in
RA pathogenesis (Bluml et al., 2011; Kurowska-Stolarska et al.,
2011). This opened the way to novel strategies in which miR-
NAs can be used as biomarkers for diagnostic, prognostic, or
theranostic purposes (Nakasa et al., 2011). Finally, therapeu-
tic intervention is also considered using small interfering RNA
(siRNA)-based gene silencing in order to dampen excessive inflam-
mation or tissue damage during RA (Apparailly and Jorgensen,
2013).
miR-19, miR-20a, AND RHEUMATOID ARTHRITIS
Fibroblast-like synoviocytes (FLS) are resident cells of the syn-
ovial membrane which play an important role in RA pathogenesis
(Bartok and Firestein, 2010). They express several TLRs and can
therefore respond to various infectious stimuli by the expression
of pro-inflammatory cytokines (Ospelt et al., 2008). Interestingly,
however, these cells secrete little or no TNF-α, IL-1, or IL-18, which
are major cytokines implicated in the inflammatory response in
RA. After we reported the involvement of miR-346 in this inhi-
bition (Alsaleh et al., 2009; Semaan et al., 2011), we performed
a global miRNA microarray analysis of FLS activated by various
TLR ligands and focused our attention on miRNAs predicted to
target components of the TLR pathways. Because we noticed that
members of the miR-17∼ 92 cluster, namely miR-19 and miR-
20, were significantly down modulated in FLS stimulated with
Lipopolysaccharide (LPS, the TLR4 ligand) or Bacterial Lipopro-
teins (BLP, a TLR2 ligand), we decided to focus on the study of the
transcriptional regulation of the entire cluster. We observed that,
as opposed to hematopoietic malignancies and solid tumors where
expression of this cluster is frequently activated, miR-17∼ 92 level
was down regulated in activated FLS isolated from RA patients
(RAFLS) (Philippe et al., 2012b). We next demonstrated that
miR-19a and b regulate TLR2 expression thereby reducing the
inflammatory response induced by BLP in FLS and which is char-
acterized by the secretion of IL-6 and Matrix metalloproteinases
(MMP-3).
More recently, we reported that miR-20, another member of the
miR-17∼ 92 cluster, also exhibits anti-inflammatory properties.
Upon targeting Ask1 mRNA, miR-20 effectively controls inflam-
matory cytokine production by FLS in response to stimulation
by the TLR4 ligand, LPS (Philippe et al., 2012a). The resulting
miR-20-dependent ASK1 repression also decreases the capacities
of FLS to secrete Il-6 or MMP-3. Previous report indicated that the
production of LPS-induced inflammatory cytokines, such as TNF-
α, IL-6, and IL-1β, is attenuated in ASK1-deficient splenocytes
and dendritic cells and that ASK1-deficient mice are resistant to
LPS-induced septic shock (Matsuzawa et al., 2005). Recently, a crit-
ical role for ASK1 in the development of RA and TNF-α-induced
production of inflammatory mediators in the joint was reported
using different animal models (Terauchi et al., 2005; Mnich et al.,
2010). This raises the possibility that ASK1 might represent a novel
therapeutic target in RA.
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THE miR-17∼ 92 CLUSTER, A GLOBAL REGULATOR OF THE
ASK1 SIGNALOSOME?
MAP Kinases are essential components of signaling pathways
involved in many cellular processes controlling cell fate: survival,
proliferation, or apoptosis (Plotnikov et al., 2011). Their acti-
vation leads to the production of pro-inflammatory molecules
which, when produced in excess or in an uncontrolled fashion,
can cause auto inflammatory diseases such as RA. ASK1, a mem-
ber of this family of kinases, is activated in response to various
stress signals, including LPS or TNF-α, which generate the produc-
tion of Reactive Oxygen Species (ROS) by an NADPH Oxydase 4
(Nox4)-dependent mechanism (Park et al., 2004; Zhao et al., 2007;
Ngkelo et al., 2012). Upon ROS production in the cytoplasm,ASK1
unbinds from thioredoxin (Trx), which enables its autophospho-
rylation and subsequent activation following TRAF2 and TRAF6
binding. The complex formed by ASK1 and Trx is designated as
the signalosome (Fujino et al., 2007).
Downstream of ASK1, additional MAP kinases, such as
MAP3K1 (also named MEKK1), are activated and the signals con-
verge on c-Jun N-terminal kinases (JNK) and p38 MAPKs (Soga
et al., 2012).
Furthermore, regulation of ASK1 expression is performed at
different levels. At the transcriptional level Ask1 is a target of the
E2F family of transcription factors. ASK1 expression is also reg-
ulated at the posttranslational level through a SOCS1-dependent
degradation process (He et al., 2006).
Figure 1 gives an overview of all these partners and their roles in
the regulation of ASK1. As noted above, we recently demonstrated
Ask1 mRNA targeting by miR-20 (Philippe et al., 2012a). We
therefore performed computational searches using TargetScan to
identify miRNA-binding motifs in the 3′UTRs of additional factors
involved in ASK1 activity. Interestingly, we observed that numer-
ous components of the “extended”ASK1 signalosome (i.e., known
factors involved in ASK1 activation as well as in the regulation
of its expression) are potentially targeted by miRNAs encoded
by the miR-17∼ 92 cluster. In addition to Ask1 transcripts, we
noted that transcription factors of the E2F family (E2F1, 2, and
3) essential for Ask1 expression are also predicted to be targets
of the miR-17/20 family. Altogether, considering that TargetScan
predicts miR-92-dependent Nox4 regulation, P38 potential regu-
lation by miR-19 and miR-18-mediated MEKK1 regulation, these
observations indicate that the miR-17∼ 92 cluster may be a global
negative regulator of ASK1 activity. Surprisingly, we observed that
SOCS1, which participates in ASK1 degradation, can as well be
targeted by miR-19, an effect opposite to those previously pre-
dicted since miR-19: SOCS1 transcripts interaction would lead to
increased ASK1 levels. However, this might also reflect a balanc-
ing essential for the necessary homeostasis during MAP kinase
activation.
As schematized in Figure 1, this analysis does not pretend to be
exhaustive and it is clear that many more miRNA: mRNA inter-
actions could be predicted. Furthermore, the expression of several
genes (e.g., Nox4, Mekk1) needs to be verified in FLS and the tar-
geting of these transcripts by the presumptive interacting miRNA
needs to be validated. Nevertheless, this model strengthens the
current assumption indicating that targeting several component
of the same pathway by different members of a miRNA cluster
likely provides a more efficient regulatory mechanism.
CONCLUDING REMARKS
Our demonstration that ASK1 regulation by miR-20a modulates
p38 phosphorylation in LPS-activated RA FLS offers interest-
ing therapeutic opportunities. In RA, p38 MAPK isoforms have
been implicated in the regulation of many processes, such as
production of pro-inflammatory mediators, migration, angiogen-
esis, osteoclast formation and differentiation, and IL-17 signaling
(Schieven, 2009). p38 involvement was demonstrated in sev-
eral animal models of RA and this has led to the development
FIGURE 1 | Global targeting of the ASK1 signalosome by members of the
miR-17∼92 cluster. The individual miRNAs encoded in the cluster are
represented by boxes whose color corresponds to the components of the
ASK1 signalosome that they are predicted to target. Proteins shown in blue
(TLR4, Trx, TRAF2, and TRAF6) do not contain miRNA-binding sites for
members of the cluster miR-17∼92 in their 3′UTR.
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of inhibitory molecules, which have recently been reported to
be efficient in several arthritis models, although their clinical
application remains to be cautiously evaluated because of the
significant side effects of these compounds (Cohen and Fleis-
chmann, 2010; Bonilla-Hernan et al., 2011). Targeting upstream
signaling mediators, such as ASK1 might minimize undesirable
off-target effects. In addition, our model predicting that sev-
eral components involved in ASK1 functions are targeted by
different members of the cluster miR-17∼ 92 creates multiple
possibilities to modulate this pathway using miRNA agonists
or antagonists. Several approaches have recently been suggested
to deliver miRNA modulators (either mimics or antagomiRs)
but in most cases, this appears a difficult task because access
to the precise cellular target is highly challenging. In the case
of RA, such pharmacological approach aiming at the modula-
tion of miRNAs activity in the synovial compartment to affect
inflammatory responses of FLS and macrophages may be more
realistic.
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